Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NGENF NERVGEN PHARMA CORP

Watchlist
1.360
-0.034-2.44%
Close 12/02 16:00 ET
High
1.400
Open
1.400
Turnover
94.43K
Low
1.310
Pre Close
1.394
Volume
69.31K
Market Cap
79.80M
P/E(TTM)
Loss
52wk High
2.540
Shares
58.68M
P/E(Static)
Loss
52wk Low
1.100
Float Cap
79.80M
Bid/Ask %
0.00%
Historical High
2.670
Shs Float
58.68M
Volume Ratio
3.54
Historical Low
1.050
Dividend TTM
--
Div Yield TTM
--
P/B
5.81
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.12%
Amplitude
6.45%
Avg Price
1.362
Lot Size
1
Float Cap
79.80M
Bid/Ask %
0.00%
Historical High
2.670
Shs Float
58.68M
Volume Ratio
3.54
Historical Low
1.050
Dividend TTM
--
P/B
5.81
Dividend LFY
--
Turnover Ratio
0.12%
Amplitude
6.45%
Avg Price
1.362
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
NervGen Pharma Corp. operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was founded by Brian J. McAlister and William Joseph Radvakon January 19, 2017 and is headquartered in Vancouver, Canada.
CEO: Mr. Paul Brennan
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist